Association between increased tumor necrosis factor alpha levels and acquired activated protein C resistance in patients with metastatic colorectal cancer

International Journal of Colorectal Disease

Volumn 27, Issue 12, 2012, Pages 1561-1567

  Ferroni, Patrizia ^a   Riondino, Silvia ^a   Portarena, Ilaria ^b   Formica, Vincenzo ^b   La Farina, Francesca ^a   Martini, Francesca ^a   Massimiani, Gioia ^b   Palmirotta, Raffaele ^a   Guadagni, Fiorella ^a   Roselli, Mario ^a,b  

^a IRCCS SAN RAFFAELE PISANA   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Activated protein C; Metastatic colorectal cancer; Tumor necrosis factor alpha; Venous thromboembolism

Indexed keywords

ANTIANEMIC AGENT; BEVACIZUMAB; BLOOD CLOTTING FACTOR 5 LEIDEN; CORTICOSTEROID; D DIMER; FLUOROURACIL; IRINOTECAN; OXALIPLATIN; TUMOR NECROSIS FACTOR ALPHA;

ACTIVATED PROTEIN C DEPENDENT THROMBIN GENERATION ASSAY; ACTIVATED PROTEIN C RESISTANCE; ADULT; AGED; ARTICLE; ASSAY; BAYES THEOREM; BLOOD ANALYSIS EQUIPMENT; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; COAGULOMETER; COLORECTAL CANCER; CONTROLLED STUDY; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; IMMUNOASSAY; KAPLAN MEIER METHOD; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; VENOUS THROMBOEMBOLISM;

EID: 84874429288     PISSN: 01791958     EISSN: 14321262     Source Type: Journal    
DOI: 10.1007/s00384-012-1493-8     Document Type: Article

References (29)

1. Sousou T, Khorana AA (2009) New insights into cancer-associated thrombosis. Arterioscler Thromb Vasc Biol 29:316-320
2. Haim N, Lanir N, Hoffman R, Haim A, Tsalik M, Brenner B (2001) Acquired activated protein C resistance is common in cancer patients and is associated with venous thromboembolism. Am J Med 110:91-96
3. Green D, Maliekel K, Sushko E, Akhtar R, Soff GA (1997) Activated-protein-C resistance in cancer patients. Haemostasis 27:112-118
4. Feffer SE, Carmosino LS, Fox RL (1989) Acquired protein C deficiency in patients with breast cancer receiving cyclophosphamide, methotrexate, and 5-fluorouracil. Cancer 63:1303-1307
5. Elice F, Fink L, Tricot G, Barlogie B, Zangari M (2006) Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism. Br J Haematol 134:399-405
6. Erman M, Abali H, Oran B, Haznedaroglu IC, Canpinar H, Kirazli S, Celik I (2004) Tamoxifen-induced tissue factor pathway inhibitor reduction: a clue for an acquired thrombophilic state? Ann Oncol 15:1622-1626
7. Ferroni P, Martini F, Portarena I, Grenga I, Riondino S, La Farina F, Laudisi A, Roselli M, Guadagni F (2011) An APC-dependent thrombin generation assay predicts chemotherapy-associated venous thromboembolism in cancer patients. Thromb Haemost 105:931-932
8. Paspatis GA, Sfyridaki A, Papanikolaou N, Triantafyllou K, Livadiotaki A, Kapsoritakis A, Lydataki N (2002) Resistance to activated protein C, factor V leiden and the prothrombin G20210A variant in patients with colorectal cancer. Pathophysiol Haemost Thromb 32:2-7
9. Negaard HFS, Iversen PO, Østenstad B, Mowinckel MC, Sandset PM (2008) Increased acquired activated protein C resistance in unselected patients with hematological malignancies. J Thromb Haemost 6:1482-1487
10. Sarig G, Miacheli Y, Lanir N, Brenner B, Haim N (2005) Mechanisms for acquired activated protein C resistance in cancer patients. J Thromb Haemost 3:589-590
11. Balkwill F (2002) Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Rev 13:135-141
12. Guadagni F, Ferroni P, Palmirotta R, Portarena I, Formica V, Roselli M (2007) TNF/VEGF cross-talking in chronic inflammation-related cancer initiation and progression: an early target in anticancer therapeutic strategy. In Vivo 21:147-162
13. Roselli M, Guadagni F, Martini F, Spila A, Mariotti S, D'Alessandro R, Aloe S, Gazzaniga PP, Basili S, Cosimelli M, Ferroni P (2003) Association between serum carcinoembryonic antigen and endothelial cell adhesion molecules in colorectal cancer. Oncology 65:132-138
14. Nikiteas NI, Tzanakis N, Gazouli M, Rallis G, Daniilidis K, Theodoropoulos G, Kostakis A, Peros G (2005) Serum IL-6, TNF-alpha and CRP levels in Greek colorectal cancer patients: prognostic implications. World J Gastroenterol 11:1639-1643
15. Rich T, Innominato PF, Boerner J, Mormont MC, Iacobelli S, Baron B, Jasmin C, Lévi F (2005) Elevated serum cytokines correlated with altered behavior, serum cortisol rhythm, and dampened 24-hour rest-activity patterns in patients with metastatic colorectal cancer. Clin Cancer Res 11:1757-1764
16. Ravasco P, Monteiro-Grillo I, Camilo M (2007) How relevant are cytokines in colorectal cancer wasting? Cancer J 13:392-398
17. Ferroni P, Roselli M, Spila A, D'Alessandro R, Portarena I, Mariotti S, Palmirotta R, Buonomo O, Petrella G, Guadagni F (2010) Serum sE-selectin levels and carcinoembryonic antigen mRNA-expressing cells in peripheral blood as prognostic factors in colorectal cancer patients. Cancer 116:2913-2921
18. Ku DH, Arkel YS, Paidas MP, Lockwood CJ (2003) Circulating levels of inflammatory cytokines (IL-1 beta and TNF-alpha), resistance to activated protein C, thrombin and fibrin generation in uncomplicated pregnancies. Thromb Haemost 90:1074-1079
19. Toulon P, Smirnov M, Triscott M, Safa O, Biguzzi E, Bouziane K, Tripodi A (2009) A new chromogenic assay (HemosIL ThromboPath) is sensitive to major prothrombotic risk factors affecting the protein C pathway. Results of a multicenter study. Thromb Res 124:137-143
20. Ferroni P, Martini F, Portarena I, Grenga I, Riondino S, La Farina F, Laudisi A, Guadagni F, Roselli M (2012) Early changes of a novel APC-dependent thrombin generation assay during chemotherapy independently predict venous thromboembolism in cancer patients. Support Cancer Care. doi: 10.1007/s00520-012-1391-1
21. Mandalà M, Barni S, Prins M, Labianca R, Tondini C, Russo L, Milesi A, Cremonesi M, Zaccanelli M, Regonesi C, Moro C, Falanga A (2010) Acquired and inherited risk factors for developing venous thromboembolism in cancer patients receiving adjuvant chemotherapy: a prospective trial. Ann Oncol 21:871-876
22. Fox EA, Kahn SR (2005) The relationship between inflammation and venous thrombosis. A systematic review of clinical studies. Thromb Haemost 94:362-365
23. Reitsma PH, Rosendaal FR (2004) Activation of innate immunity in patients with venous thrombosis: the Leiden Thrombophilia Study. J Thromb Haemost 2:619-622
24. Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow? Lancet 257:539-545
25. Guadagni F, Ferroni P, Basili S, Facciolo F, Carlini S, Crecco M, Martini F, Spila A, Mineo TC, Roselli M (2004) Correlation between tumor necrosis factor-alpha and D-dimer levels in non-small cell lung cancer patients. Lung Cancer 44:303-310
26. van Aken BE, den Heijer M, Bos GM, van Deventer SJ, Reitsma PH (2000) Recurrent venous thrombosis and markers of inflammation. Thromb Haemost 83:536-539
27. Johnson K, Aarden L, Choi Y, De Groot E, Creasey A (1996) The proinflammatory cytokine response to coagulation and endotoxin in whole blood. Blood 87:5051-5060
28. Di Nisio M, Ferrante N, De Tursi M, Iacobelli S, Cuccurullo F, Büller HR, Feragalli B, Porreca E (2010) Incidental venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Thromb Haemost 104:1049-1054
29. Ferroni P, Formica V, Roselli M, Guadagni F (2010) Thromboembolic events in patients treated with anti-angiogenic drugs. Curr Vasc Pharmacol 8:102-113